Lincoln Pharmaceuticals' Q1 FY 2026-27 Quarterly Results

Result Summary

• Lincoln Pharmaceuticals Ltd reported a 10.1% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Jun (Q1 FY 2026-27). On a year-on-year (YoY) basis, it witnessed a growth of 19.0%.
• Its expenses for the quarter were down by 7.4% QoQ and up 15.0% YoY.
• The net profit increased 211.5% QoQ and increased 30.9% YoY.
• The earnings per share (EPS) of Lincoln Pharmaceuticals Ltd stood at 18.09 during Q1 FY 2026-27.

Financial Statments for Q1 FY 2026-27

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Lincoln Pharmaceuticals Ltd is a prominent player in the pharmaceutical industry, engaged in the development, manufacturing, and distribution of a wide range of pharmaceutical formulations. The company primarily focuses on producing therapeutics for various ailments, including cardiovascular diseases, antibiotics, anti-inflammatory drugs, and other healthcare products. Lincoln Pharmaceuticals operates with a commitment to quality and innovation, which is evident in its robust product portfolio. As of the latest available information, there are no specific recent major developments disclosed regarding the company.

Revenue

Lincoln Pharmaceuticals Ltd reported a total income of ₹201.55 crores in Q1FY27, marking a significant increase of 10.1% from the previous quarter (Q4FY26) and a 19.0% rise compared to Q1FY26. This growth reflects a strong upward trajectory in revenue generation, showing an effective quarter-over-quarter and year-over-year performance. The company's ability to augment its revenue streams over the examined periods demonstrates its robust operational capabilities in the pharmaceutical sector.

Profitability

The financial performance of Lincoln Pharmaceuticals Ltd in Q1FY27 exhibits notable profitability metrics. The company recorded a Profit Before Tax (PBT) of ₹47.55 crores, a substantial increase of 184.7% from the preceding quarter, and a 34.4% rise on a year-over-year basis. The Profit After Tax (PAT) stood at ₹36.23 crores, achieving a remarkable quarter-over-quarter growth of 211.5% and a year-over-year increase of 30.9%. These figures underline the company's efficient cost management and strong profit margins. Additionally, the Earnings Per Share (EPS) for Q1FY27 was ₹18.09, reflecting similar growth patterns as PAT, with an impressive surge of 211.4% QoQ and 30.9% YoY.

Operating Metrics

During Q1FY27, Lincoln Pharmaceuticals Ltd maintained effective operational control, as evidenced by its total expenses of ₹153.99 crores. This figure denotes a decrease of 7.4% from the previous quarter, while still marking a 15.0% increase year-over-year. The reduction in expenses QoQ amidst rising revenue indicates a favorable operating environment. The tax expenses for the period amounted to ₹11.32 crores, which saw an increase of 123.3% from Q4FY26 and a 46.8% rise from Q1FY26. These tax figures align with the overall profitability increase, reflecting the company's improved financial standing within this quarter.